23731973|t|Dexmedetomidine use in the ICU: are we there yet?
23731973|a|CITATION: Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, Bratty JR, Takala J; Dexmedeto midine for Long-Term Sedation Investigators: Dexmedetomidine vesus midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012, 307:1151-1160. BACKGROUND: Long-term sedation with midazolam or propofol in intensive care units (ICUs) has serious adverse effects. Dexmedetomidine, an alpha-2 agonist available for ICU sedation, may reduce the duration of mechanical ventilation and enhance patient comfort. METHODS:  OBJECTIVE: The objective was to determine the efficacy of dexmedetomidine versus midazolam or propofol (preferred usual care) in maintaining sedation, reducing duration of mechanical ventilation, and improving patients' interaction with nursing care. DESIGN: Two phase 3 multicenter, randomized, double-blind trials were conducted. SETTING: The MIDEX (Midazolam vs. Dexmedetomidine) trial compared midazolam with dexmedetomidine in ICUs of 44 centers in nine European countries. The PRODEX (Propofol vs. Dexmedetomidine) trial compared propofol with dexmedetomidine in 31 centers in six European countries and two centers in Russia. SUBJECTS: The subjects were adult ICU patients who were receiving mechanical ventilation and who needed light to moderate sedation for more than 24 hours.Intervention: After enrollment, 251 and 249 subjects were randomly assigned midazolam and dexmedetomidine,respectively, in the MIDEX trial, and 247 and 251 subjects were randomly assigned propofol and dexmedetomidine, respectively, in the PRODEX trial. Sedation with dexmedetomidine dexmedetomidine,midazolam, or propofol; daily sedation stops; and spontaneous breathing trials were employed. OUTCOMES: For each trial, investigators tested whether dexmedetomidine was noninferior to control with respect to proportion of time at target sedation level(measured by Richmond Agitation Sedation Scale) and superior to control with respect to duration of mechanical ventilation. Secondary end points were the ability of the patient to communicate pain (measured by using a visual analogue scale [VAS]) and length of ICU stay. Time at target sedation was analyzed in per-protocol(midazolam, n=233, versus dexmedetomidine, n=227; propofol, n=214, versus dexmedetomidine, n=223) population. RESULTS: Dexmedetomidine/midazolam ratio in time at target sedation was 1.07 (95% confidence interval (CI) 0.97 to 1.18), and dexmedetomidine/propofol ratio in time at target sedation was 1.00 (95% CI 0.92 to 1.08). Median duration of mechanical ventilation appeared shorter with dexmedetomidine (123 hours, interquartile range (IQR) 67 to 337) versus midazolam (164 hours, IQR 92 to 380; P=0.03) but not with dexmedetomidine (97 hours, IQR 45 to 257) versus propofol (118 hours, IQR 48 to 327; P=0.24). Patient interaction (measured by using VAS) was improved with dexmedetomidine (estimated score difference versus midazolam 19.7, 95% CI 15.2 to 24.2; P<0.001; and versus propofol 11.2, 95% CI 6.4 to 15.9; P<0.001). Lengths of ICU and hospital stays and mortality rates were similar. Dexmedetomidine versus midazolam patients had more hypotension (51/247 [20.6%] versus 29/250 [11.6%]; P=0.007) and bradycardia (35/247 [14.2%] versus 13/250 [5.2%]; P<0.001). CONCLUSIONS: Among ICU patients receiving prolonged mechanical ventilation, dexmedetomidine was not inferior to midazolam and propofol in maintaining light to moderate sedation. Dexmedetomidine reduced duration of mechanical ventilation compared with midazolam and improved the ability of patients to communicate pain compared with midazolam and propofol. Greater numbers of adverse effects were associated with dexmedetomidine.
23731973	0	15	Dexmedetomidine	Chemical	MESH:D020927
23731973	150	166	Dexmedeto midine	Chemical	MESH:D020927
23731973	205	220	Dexmedetomidine	Chemical	MESH:D020927
23731973	227	236	midazolam	Chemical	MESH:D008874
23731973	240	248	propofol	Chemical	MESH:D015742
23731973	399	408	midazolam	Chemical	MESH:D008874
23731973	412	420	propofol	Chemical	MESH:D015742
23731973	481	496	Dexmedetomidine	Chemical	MESH:D020927
23731973	501	508	alpha-2	Gene	170589
23731973	607	614	patient	Species	9606
23731973	692	707	dexmedetomidine	Chemical	MESH:D020927
23731973	715	724	midazolam	Chemical	MESH:D008874
23731973	728	736	propofol	Chemical	MESH:D015742
23731973	844	852	patients	Species	9606
23731973	986	995	Midazolam	Chemical	MESH:D008874
23731973	1000	1015	Dexmedetomidine	Chemical	MESH:D020927
23731973	1032	1041	midazolam	Chemical	MESH:D008874
23731973	1047	1062	dexmedetomidine	Chemical	MESH:D020927
23731973	1125	1133	Propofol	Chemical	MESH:D015742
23731973	1138	1153	Dexmedetomidine	Chemical	MESH:D020927
23731973	1170	1178	propofol	Chemical	MESH:D015742
23731973	1184	1199	dexmedetomidine	Chemical	MESH:D020927
23731973	1305	1313	patients	Species	9606
23731973	1497	1506	midazolam	Chemical	MESH:D008874
23731973	1511	1526	dexmedetomidine	Chemical	MESH:D020927
23731973	1609	1617	propofol	Chemical	MESH:D015742
23731973	1622	1637	dexmedetomidine	Chemical	MESH:D020927
23731973	1688	1703	dexmedetomidine	Chemical	MESH:D020927
23731973	1704	1719	dexmedetomidine	Chemical	MESH:D020927
23731973	1720	1729	midazolam	Chemical	MESH:D008874
23731973	1734	1742	propofol	Chemical	MESH:D015742
23731973	1869	1884	dexmedetomidine	Chemical	MESH:D020927
23731973	2140	2147	patient	Species	9606
23731973	2163	2167	pain	Disease	MESH:D010146
23731973	2295	2304	midazolam	Chemical	MESH:D008874
23731973	2320	2335	dexmedetomidine	Chemical	MESH:D020927
23731973	2344	2352	propofol	Chemical	MESH:D015742
23731973	2368	2383	dexmedetomidine	Chemical	MESH:D020927
23731973	2413	2428	Dexmedetomidine	Chemical	MESH:D020927
23731973	2429	2438	midazolam	Chemical	MESH:D008874
23731973	2530	2545	dexmedetomidine	Chemical	MESH:D020927
23731973	2546	2554	propofol	Chemical	MESH:D015742
23731973	2684	2699	dexmedetomidine	Chemical	MESH:D020927
23731973	2756	2765	midazolam	Chemical	MESH:D008874
23731973	2814	2829	dexmedetomidine	Chemical	MESH:D020927
23731973	2863	2871	propofol	Chemical	MESH:D015742
23731973	2908	2915	Patient	Species	9606
23731973	2970	2985	dexmedetomidine	Chemical	MESH:D020927
23731973	3021	3030	midazolam	Chemical	MESH:D008874
23731973	3078	3086	propofol	Chemical	MESH:D015742
23731973	3191	3206	Dexmedetomidine	Chemical	MESH:D020927
23731973	3214	3223	midazolam	Chemical	MESH:D008874
23731973	3224	3232	patients	Species	9606
23731973	3242	3253	hypotension	Disease	MESH:D007022
23731973	3306	3317	bradycardia	Disease	MESH:D001919
23731973	3389	3397	patients	Species	9606
23731973	3442	3457	dexmedetomidine	Chemical	MESH:D020927
23731973	3478	3487	midazolam	Chemical	MESH:D008874
23731973	3492	3500	propofol	Chemical	MESH:D015742
23731973	3544	3559	Dexmedetomidine	Chemical	MESH:D020927
23731973	3617	3626	midazolam	Chemical	MESH:D008874
23731973	3655	3663	patients	Species	9606
23731973	3679	3683	pain	Disease	MESH:D010146
23731973	3698	3707	midazolam	Chemical	MESH:D008874
23731973	3712	3720	propofol	Chemical	MESH:D015742
23731973	3778	3793	dexmedetomidine	Chemical	MESH:D020927
23731973	Positive_Correlation	MESH:D008874	MESH:D007022
23731973	Positive_Correlation	MESH:D008874	MESH:D001919
23731973	Comparison	MESH:D008874	MESH:D020927
23731973	Positive_Correlation	MESH:D020927	170589
23731973	Positive_Correlation	MESH:D015742	MESH:D001919
23731973	Positive_Correlation	MESH:D020927	MESH:D001919
23731973	Comparison	MESH:D008874	MESH:D015742
23731973	Cotreatment	MESH:D015742	MESH:D020927
23731973	Positive_Correlation	MESH:D015742	MESH:D007022
23731973	Positive_Correlation	MESH:D020927	MESH:D007022

